ECCO26 data reinforce long-term durability and real-world impact of AbbVie’s IBD portfolio Real-world data and three-year trial results show sustained remission and symptom control with Skyrizi and Rinvoq.

New data at ECCO 2026: Risankizumab & upadacitinib show sustained remission & real-world impact in UC & Crohn’s. Experts discuss 3-year durability, rapid symptom control & what it means for patients.
#News #ECCO26 #IBD #SKYRIZI #RINVOQ #RealWorldEvidence #AbbVie

ECCO26 data reinforce long-term durability and real-world impact of AbbVie’s IBD portfolio Real-world data and three-year trial results show sustained remission and symptom control with Skyrizi and Rinvoq.

New data at ECCO 2026: Risankizumab & upadacitinib show sustained remission & real-world impact in UC & Crohn’s. Experts discuss 3-year durability, rapid symptom control & what it means for patients.
#News #ECCO26 #IBD #SKYRIZI #RINVOQ #RealWorldEvidence #AbbVie

AbbVie Seeks FDA and EMA Approval for RINVOQ® in Vitiligo Treatment for All Ages AbbVie has submitted regulatory applications to the FDA and EMA for RINVOQ® targeting vitiligo in both adults and adolescents, addressing unmet medical needs.

AbbVie Seeks FDA and EMA Approval for RINVOQ® in Vitiligo Treatment for All Ages #USA #AbbVie #North_Chicago #RINVOQ #Vitiligo

Having a family dr who listens is my saving grace while dealing with crippling PsA. My rheum dr is good too. I have heard nightmare stories, so even though we are still trialing to find a med that works - at least i’m acknowledged
#chronicpain #psoriaticarthritis #rinvoq #talz #methotrexate

AbbVie's Third-Quarter 2025 Financial Performance Released: Key Insights and Expectations AbbVie has revealed its financial results for Q3 2025, noting significant changes in earnings. This article examines the figures and the company's outlook.

AbbVie's Third-Quarter 2025 Financial Performance Released: Key Insights and Expectations #United_States #AbbVie #North_Chicago #Skyrizi #RINVOQ

AbbVie Reports Encouraging Results for Upadacitinib in Vitiligo Treatment Trials Recent Phase 3 studies show that AbbVie's upadacitinib significantly reduces vitiligo symptoms in adults and adolescents, marking a breakthrough in treatment options.

AbbVie Reports Encouraging Results for Upadacitinib in Vitiligo Treatment Trials #USA #North_Chicago #RINVOQ #Upadacitinib #Vitiligo

RINVOQ® Outperforms HUMIRA® in Head-to-Head Study for RA Treatment A recent head-to-head clinical trial reveals RINVOQ's superiority over HUMIRA in achieving low disease activity in rheumatoid arthritis patients.

RINVOQ® Outperforms HUMIRA® in Head-to-Head Study for RA Treatment #USA #North_Chicago #rheumatoid_arthritis #Humira #RINVOQ

FDA Approves RINVOQ® for Expanded Use Against Inflammatory Bowel Disease The FDA has approved RINVOQ® for expanded use in treating inflammatory bowel diseases, making it a vital option for patients unable to use TNF blockers.

FDA Approves RINVOQ® for Expanded Use Against Inflammatory Bowel Disease #USA #AbbVie #North_Chicago #IBD #RINVOQ

Is it just me, or to #pharmaceutical companies naming #drugs ridiculous names on purpose?

#ubrelvy #rinvoq

What does #RinVoq have to do with a little league home plate umpire?

AbbVie Celebrates Positive Outcomes from Second Phase 3 Study of Upadacitinib for Alopecia Areata AbbVie announces encouraging results from the Phase 3 trial of upadacitinib (RINVOQ®) for alopecia areata, showing significant hair regrowth at 24 weeks.

AbbVie Celebrates Positive Outcomes from Second Phase 3 Study of Upadacitinib for Alopecia Areata #United_States #North_Chicago #Alopecia_Areata #RINVOQ #Upadacitinib

AbbVie's Second Quarter 2025 Financial Results: Mixed Performance Highlights Growth Potential AbbVie has released its financial results for Q2 2025, showcasing a rise in adjusted earnings despite a notable dip in GAAP earnings. Key insights reveal strengths in immunology and neuroscience sectors.

AbbVie's Second Quarter 2025 Financial Results: Mixed Performance Highlights Growth Potential #USA #AbbVie #North_Chicago #Skyrizi #RINVOQ

AbbVie's UP-AA Trial Shows Promising Results for Alopecia Areata Treatment with Upadacitinib AbbVie's Phase 3 UP-AA trial results showcase upadacitinib as a potent treatment for severe alopecia areata, changing lives for many affected.

AbbVie's UP-AA Trial Shows Promising Results for Alopecia Areata Treatment with Upadacitinib #USA #AbbVie #North_Chicago #Alopecia_Areata #RINVOQ

AbbVie Receives Approval for Rinvoq to Treat Giant Cell Arteritis in Japan AbbVie announces additional approval for Rinvoq in Japan, providing a new treatment option for adults with giant cell arteritis who have not responded to existing therapies.

AbbVie Receives Approval for Rinvoq to Treat Giant Cell Arteritis in Japan #Japan #AbbVie #RINVOQ #Giant_Cell_Arteritis #Minato_City

Rinvoq Approval: A New Hope for Giant Cell Arteritis Patients AbbVie announces FDA approval for Rinvoq as a groundbreaking treatment for adult patients with Giant Cell Arteritis, marking a significant advancement in care.

Rinvoq Approval: A New Hope for Giant Cell Arteritis Patients #USA #North_Chicago #RINVOQ #Upadacitinib #GCA

Me over the past years. I’m stable . 😀😌 #StableHealth #UlcerativeColitis #Treatment #Rinvoq #Happy #Yes #NewMe

This Arthritis Awareness Month, learn how you could get Humira, Rinvoq, or Skyrizi at no cost through myAbbVie Assist. Find a program that covers your medication at www.needymeds.org/pap

#arthritis #arthritisawareness #arthritisawarenessmonth #rheumatoidarthritis #humira #skyrizi #rinvoq

New EU Approval for Rinvoq as Treatment for Giant Cell Arteritis in Adults AbbVie has received EU approval for Rinvoq, making it the first oral JAK inhibitor for adult patients with giant cell arteritis, offering new hope for better treatment outcomes.

New EU Approval for Rinvoq as Treatment for Giant Cell Arteritis in Adults #None #AbbVie #RINVOQ #Giant_Cell_Arteritis

AbbVie's Strong Revenue Growth in Q1 2025 Shows Promising Future AbbVie's Q1 2025 financial performance demonstrates significant growth, particularly in immunology and neuroscience portfolios, reflecting a robust business strategy.

AbbVie's Strong Revenue Growth in Q1 2025 Shows Promising Future #USA #AbbVie #North_Chicago #Skyrizi #RINVOQ

AbbVie’s Rinvoq receives EC approval to treat adults with giant cell arteritis - PMLiVE The drug is now the first oral JAK inhibitor to be approved in the EU for this patient population

#AbbVie #Rinvoq #upadacitinib #giantcellarteritis #oralJAKinhibitor #JAKinhibitor #marketingauthorisation #Januskinaseinhibitor #SELECTGCAtrial #immunology #pharma #pharmaceuticals
zurl.co/ovP8I

AbbVie Receives EU Approval for RINVOQ® to Treat Giant Cell Arteritis AbbVie has announced the European Commission's approval for RINVOQ, the first oral JAK inhibitor for adults with giant cell arteritis, providing a new therapeutic option.

AbbVie Receives EU Approval for RINVOQ® to Treat Giant Cell Arteritis #None #AbbVie #RINVOQ #Giant_Cell_Arteritis

See how the line is going down. I'm so proud of my treatment ! 😲😳♥️ It's from June 2023 to December 2024. It represents the inflammation level in my poop. 😳 #UlcerativeColitis #Wow #Impressed #Nice #Rinvoq #Happy #Cool

AbbVie Acquires Nimble Therapeutics in $200M Deal to Strengthen Immunology Pipeline AbbVie has announced its acquisition of Nimble Therapeutics for $200 million upfront, marking another significant move in the pharma giant's strategic efforts to bolster its long-term growth prospects...

www.linkedin.com/pulse/abbvie...

AbbVie Acquires Nimble Therapeutics in $200M Deal to Strengthen Immunology Pipeline

kstrategyand.com/pharma-news

#AbbVie #NimbleTherapeutics #Immunology #AutoimmuneDiseases #Skyrizi #Rinvoq #InflammatoryBowelDiseases #Neuroscience#Humanteconomy #Humantec

Original post on mstdn.social

It’s been about a yr since I’ve done a hashtag post—I think it’s time! #RockAndRoll #SoCal #DesertLife #EVs #ChronicIllness #AutoImmuneIllness #PsoriaticSpondylitis #Rinvoq #Dogs #DogsOfMastodon #Abortion #AbortionRightsAreHumanRights #AbortionIsHealthcare #Adoption #AdopteesOfMastodon […]

Meine Entscheidung fiel auf #Rinvoq
Tabletten.
Da alles andere, Spritzen, Infusion, für mich ohne #Fahrdienst oder ähnlichem, derzeit nicht praktikabel ist.

Wenn ich wüsste dass das small molecule Etrasimod ähnlich wirksam wie #Rinvoq ist dann würde ich meine #Pfizer Position weiter ausbauen.

I think it’s been long enough that I can make this announcement 📣

Rinvoq has been a serious game changer for me!
I haven’t felt this good in decades!
#Rinvoq #Abvvie #AnkylosingSpondylitis #ChronicPain #Spoonie